Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis

Neurology

Volumn 76, Issue 14, 2011, Pages 1206-1213

  Kuhle, J ^a   Leppert, D ^a   Petzold, A ^d,e   Regeniter, A ^b   Schindler, C ^c   Mehling, M ^a   Anthony, D C ^f   Kappos, L ^a   Lindberg, R L P ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Laboratory Medicine   (Switzerland)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA1A INTERFERON; BIOLOGICAL MARKER; IMMUNOGLOBULIN; MITOXANTRONE; NEUROFILAMENT PROTEIN; NFHSMI35 PROTEIN; RITUXIMAB; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ADULT; AGING; ARTICLE; BLOOD BRAIN BARRIER; CELL COUNT; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CLINICALLY ISOLATED SYNDROME; CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE DURATION; ELECTROCHEMILUMINESCENCE IMMUNOASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HEAVY CHAIN; HUMAN; IMMUNOASSAY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE DEGENERATION; PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RELAPSE; SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS; SYNDROME;

EID: 79954568567     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31821432ff     Document Type: Article

References (40)

1. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132:1175-1189.
2. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med;338:278-285.
3. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002;125:2202-2212.
4. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Bruck W. Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 2000;123: 1174-1183. (Pubitemid 30312109)
5. Van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46:747-754. (Pubitemid 29518136)
6. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000;48:893-901.
7. Silber E, Sharief MK. Axonal degeneration in the pathogenesis of multiple sclerosis. J Neurol Sci 1999;170:11-18. (Pubitemid 29502529)
8. De Waegh SM, Lee VM, Brady ST. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell 1992; 68:451-463.
9. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183-198. (Pubitemid 40804835)
10. Petzold A, Keir G, Warren J, Fox N, Rossor MN. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis 2007;4:185-194. (Pubitemid 47000412)
11. Teunissen CE, Dijkstra C, Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005;4:32-41. (Pubitemid 40023234)
12. Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;66:852-856. (Pubitemid 43739759)
13. Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM. CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 2007;28:742-747. (Pubitemid 46349352)
14. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:402-404. (Pubitemid 28159853)
15. Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003;61:1720-1725. (Pubitemid 38020818)
16. Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003;987: 25-31. (Pubitemid 37267883)
17. Petzold A, Eikelenboom MJ, Keir G, et al. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. J Neurol Neurosurg Psychiatry 2005;76:206-211. (Pubitemid 40143709)
18. Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009;72:1322-1329.
19. Salzer J, Svenningsson A, Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult Scler 2010;16:287-292.
20. Kuhle J, Regeniter A, Leppert D, et al. A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein. J Neuroimmunol Epub 2010 Jan 29.
21. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003;278: 179-190. (Pubitemid 37281201)
22. Abdo WF, Van De Warrenburg BP, Munneke M, et al. CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology 2006;67: 474-479. (Pubitemid 44214973)
23. Shaw G, Yang C, Ellis R, et al. Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem Biophys Res Commun 2005;336:1268-1277. (Pubitemid 41383458)
24. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005;58:840-846. (Pubitemid 41746873)
25. Rudick R, Antel J, Confavreux C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996;40: 469-479. (Pubitemid 26304809)
26. Felgenhauer K, Schliep G, Rapic N. Evaluation of the blood-CSF barrier by protein gradients and the humoral immune response within the central nervous system. J Neurol Sci 1976;30:113-128.
27. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders: III: evaluation of IgG synthe- sis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest 1977;37:397-401. (Pubitemid 8387873)
28. Keir G, Luxton RW, Thompson EJ. Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update. Ann Clin Biochem 1990;27:436-443. (Pubitemid 20340288)
29. Reiber H, Felgenhauer K. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta 1987;163:319-328. (Pubitemid 17050086)
30. May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI. Cerebrospinal fluid production is reduced in healthy aging. Neurology 1990;40:500-503. (Pubitemid 20117538)
31. Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci 2003;21:79-96. (Pubitemid 37330250)
32. Reiber H, Peter JB. Cerebrospinal fluid analysis: diseaserelated data patterns and evaluation programs. J Neurol Sci 2001;184:101-122. (Pubitemid 32178265)
33. Arnold F. [Cerebrospinal fluid analysis in healthy persons and multiple sclerosis patients.] Schweiz Med Wochenschr 1966;96:1098-1103.
34. Mertin J, Wisser H, Doerr P. [Studies on the normal concentration range of total protein and the total protein fractions of the cerebrospinal fluid by electrophoresis on cellulose acetate (author's transl).] Z Klin Chem Klin Biochem 1971;9:337-340.
35. Jung PR, Rieder HP, Jeltsch C. [Total protein levels in lumbar cerebrospinal fluid of normal subjects (author's transl).] Klin Wochenschr 1973;51:810-816.
36. Eikelenboom MJ, Petzold A, Lazeron RH, et al. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003;60:219-223. (Pubitemid 36152012)
37. Brettschneider J, Petzold A, Junker A, Tumani H. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis. Mult Scler 2006;12: 143-148.
38. Rejdak K, Petzold A, Stelmasiak Z, Giovannoni G. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler 2008;14:59-66. (Pubitemid 351541397)
39. Giovannoni G. Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the 'spinal tap.' Mult Scler 2010;16:285-286.
40. Bar-Or A. The immunology of multiple sclerosis. Semin Neurol 2008;28:29-45. (Pubitemid 351273082)